rs104894008 — GCK Gly261Arg (MODY2)

GCK Gly261Arg — The Glucose Sensor With a Broken Dial

Every time you eat, your pancreatic beta cells must sense the rising tide of glucose and respond by secreting exactly the right amount of insulin. This sensing is performed almost entirely by a single enzyme: glucokinase (GCK), often called the glucose sensor of the pancreas¹¹ glucose sensor of the pancreas
Glucokinase acts as a "glucose sensor" by phosphorylating glucose to glucose-6-phosphate; its sigmoidal kinetics and low affinity for glucose make it uniquely suited to respond proportionally to physiological glucose concentrations. The Gly261Arg variant (c.781G>A) nearly destroys this sensing function, causing maturity-onset diabetes of the young type 2 — a monogenic, autosomal dominant form of diabetes with a clinical profile entirely unlike type 1 or type 2 diabetes.

The Mechanism

Glycine at position 261 sits within a structurally critical loop of the glucokinase protein, adjacent to the enzyme's active site. The p.Gly261Arg substitution²² The p.Gly261Arg substitution
A glycine-to-arginine change introduces a large, positively charged side chain into a tight structural loop, disrupting the enzyme's conformational flexibility required for substrate binding replaces the smallest amino acid (glycine) with one of the largest and most charged (arginine), distorting the loop geometry and preventing normal glucose binding. Kinetic assays of recombinant Gly261Arg glucokinase show a relative activity index (RAI) of just 0.02³³ relative activity index (RAI) of just 0.02
RAI integrates Vmax, Km for glucose, and the Hill coefficient into a single measure of physiological efficacy; wild-type GCK has RAI = 1.0, and the ClinGen MODY expert panel uses a threshold of 0.50 to classify a variant as causing disease — below the 0.50 threshold that defines disease causation.

In a heterozygous carrier, one working copy of GCK remains. The result is a pancreas with half-normal glucose-sensing capacity: the set-point for insulin release is shifted upward by approximately 1.4–2.0 mmol/L⁴⁴ shifted upward by approximately 1.4–2.0 mmol/L
This stable upward shift in the glucose threshold means the pancreas defends a higher fasting glucose — roughly 5.5–8.0 mmol/L rather than the normal 3.9–5.5 mmol/L — throughout the carrier's entire life. The glucose is stably elevated, not progressively worsening.

The Evidence

Kinetic characterization⁵⁵ Kinetic characterization
Cuesta-Muñoz AL et al. Clinical heterogeneity in monogenic diabetes caused by mutations in the glucokinase gene (GCK-MODY). Diabetes Care, 2010 of recombinant Gly261Arg glucokinase confirmed near-abolition of activity (RAI 0.02), meeting the ClinGen Monogenic Diabetes Expert Panel's pathogenicity criteria for functional evidence. This functional evidence, combined with segregation in multiple MODY families and absence from population databases, underpins the expert panel's Pathogenic classification⁶⁶ expert panel's Pathogenic classification
ClinVar VCV000016135, reviewed by ClinGen Monogenic Diabetes Variant Curation Expert Panel, August 2023.

Velho et al. 1997⁷⁷ Velho et al. 1997
Velho G et al. Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia, 1997 established the canonical GCK-MODY clinical picture across 42 families: mild fasting hyperglycemia (mean 6.9 mmol/L), HbA1c typically 5.8–7.6%, no progression over decades, and very low rates of microvascular complications compared to type 2 diabetes.

Bennett et al. 2011⁸⁸ Bennett et al. 2011
Bennett K et al. Four novel cases of permanent neonatal diabetes mellitus caused by homozygous mutations in the glucokinase gene. Pediatric Diabetes, 2011 reported homozygous GCK mutations causing permanent neonatal diabetes — insulin-dependent from birth, with onset in the first weeks of life. This defines the homozygous phenotype as a distinct, severe condition requiring lifelong insulin therapy.

Practical Implications

For heterozygous carriers, the central insight is: this is not type 2 diabetes. The hyperglycemia is stable, congenital, and rarely worsens over a lifetime. Large retrospective analyses⁹⁹ Large retrospective analyses
Shields BM et al. 2021 multicenter cohort show that most GCK-MODY heterozygotes do not develop progressive microvascular complications, and the vast majority do not need pharmacological treatment — lifestyle changes sufficient for type 2 diabetes are unnecessary and typically ineffective at "correcting" GCK-MODY because the elevated glucose is the set-point, not a pathological deviation from it.

The key action is accurate diagnosis: many GCK-MODY carriers are misdiagnosed as type 1 or type 2 diabetes and placed on unnecessary insulin or oral hypoglycemic therapy. Correct genetic diagnosis avoids inappropriate treatment and guides family screening (first-degree relatives have a 50% chance of carrying the variant).

Pregnancy is the main exception. If the fetus does not inherit the GCK variant, maternal GCK-MODY hyperglycemia can cause fetal macrosomia and treatment may be warranted. If the fetus also inherits the variant, no treatment is needed. Fetal genotyping or indirect assessment via ultrasound growth monitoring guides management.

Interactions

GCK-MODY heterozygotes carrying additional common type 2 diabetes risk variants (such as rs5219 in KCNJ11, or rs7903146 in TCF7L2) may have a modestly worse glycemic trajectory over decades, as these common variants impair the remaining functional glucokinase copy's downstream pathway. Clinically, the GCK-MODY phenotype typically dominates.

For family members: because this variant is autosomal dominant, a confirmed MODY2 diagnosis in one family member should prompt clinical evaluation of parents, siblings, and children — cascade screening by genetic testing or fasting glucose is the standard approach.